ClinicalTrials.gg
CompletedNCT04817644Updated Mar 11, 2025

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

A Phase 1 interventional study of Oral semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
156th of 163
14 · median 104
Started
2021
with 9 others
Phase 1
41 of 163
3 open now
Registered
84th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 156th largest by enrollment, is one of 10 that started in 2021, is one of 41 in phase 1, and was the 84th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg semaglutide.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, female subjects who have given birth at least 3 months prior to screening and who breastfeed (breastfeeding is defined by feeding the baby milk produced by the mother. Using a breast pump to collect milk and subsequently feeding it to the baby by bottle, is also defined as breastfeeding ) their infant to an extent, where the majority of the infant's total energy intake is from breastfeeding and sufficient milk is produced to fulfil the trial requirements, as judged by the investigator.
  • Agree to abstain from breastfeeding their infant from first dose of oral semaglutide to the "End of trial" visit (total of 47 days) to avoid potentially exposing their child to semaglutide and SNAC.
  • The breastfed infant is able to feed from a bottle (expenses related to alternative infant nutrition during trial participation will be covered by Novo Nordisk) prior to screening.
  • Age above or equal to 18 years at the time of agreement to take part.
  • (BMI) between 20.0 and 32.4 kg/m\^2 (both inclusive).

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant or intends to become pregnant or is of and not using an effective method.
  • (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at screening.
  • Presence of gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
  • History (as declared by the subject or reported in the medical records) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
  • Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the subject or reported in the medical records).
  • Presence or history (as declared by the subject or reported in the medical records) of malignant neoplasm within 5 years prior to the day of screening (basal or squamous cell skin cancer, or any carcinoma in-situ is allowed).
  • Presence or history (as declared by the subject or reported in the medical records) of pancreatitis (acute or chronic).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Oral semaglutide

    All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.

    Drug: Oral semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)

    nmol\*h/L

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  2. Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

Secondary outcomes

  1. Average semaglutide milk concentration during a dosing interval after the 10th dosing (Cavg,sema,D10,milk)

    nmol/L

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  2. Maximum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,milk)

    nmol/L

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  3. Minimum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmin,sema,D10,milk)

    nmol/L

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  4. Time to maximum semaglutide milk concentration during a dosing interval after the 10th dosing (tmax,sema,D10,milk)

    Hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  5. Estimated daily infant semaglutide dose

    mg/kg/day

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  6. Relative daily infant semaglutide dose

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  7. Average SNAC milk concentration during a dosing interval after the 10th dosing (Cavg,SNAC,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  8. Maximum SNAC milk concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  9. Minimum SNAC milk concentration during a dosing interval after the 10th dosing (Cmin,SNAC,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  10. Time to maximum SNAC milk concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,milk)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  11. Estimated daily infant SNAC dose

    ng/kg/day

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  12. Relative daily infant SNAC dose

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  13. Area under the SNAC metabolite E494 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,milk)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  14. Average SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cavg,E494,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  15. Maximum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  16. Minimum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmin,E494,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  17. Time to maximum SNAC metabolite E494 milk concentration after the 10th dosing (tmax,E494,D10,milk)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  18. Estimated daily infant SNAC metabolite E494 dose

    ng/kg/day

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  19. Area under the SNAC metabolite E506 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,milk)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  20. Average SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cavg,E506,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  21. Maximum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  22. Minimum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmin,E506,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  23. Time to maximum SNAC metabolite E506 milk concentration after the 10th dosing (tmax,E506,D10,milk)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  24. Estimated daily infant SNAC metabolite E506 dose

    ng/kg/day

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  25. Area under the SNAC metabolite E1245 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,milk)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  26. Average SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cavg,E1245,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  27. Maximum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  28. Minimum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmin,E1245,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  29. Time to maximum SNAC metabolite E1245 milk concentration after the 10th dosing (tmax,E1245,D10,milk)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  30. Estimated daily infant SNAC metabolite E1245 dose

    ng/kg/day

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  31. Area under the SNAC metabolite E1246 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,milk)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  32. Average SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cavg,E1246,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  33. Maximum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  34. Minimum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmin,E1246,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  35. Time to maximum SNAC metabolite E1246 milk concentration in milk after the 10th dosing (tmax,E1246,D10,milk)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  36. Estimated daily infant SNAC metabolite E1246 dose

    ng/kg/day

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  37. Area under the SNAC metabolite E1247 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,milk)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  38. Average SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cavg,E1247,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  39. Maximum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  40. Minimum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmin,E1247,D10,milk)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  41. Time to maximum SNAC metabolite E1247 milk concentration after the 10th dosing (tmax,E1247,D10,milk)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  42. Estimated daily infant SNAC metabolite E1247 dose

    ng/kg/day

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  43. Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,plasma)

    nmol\*h/L

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  44. Maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,plasma)

    nmol/L

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  45. Time to maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (tmax,sema,D10,plasma)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  46. Area under the SNAC plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,plasma)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  47. Maximum SNAC plasma concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,plasma)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  48. Time to maximum SNAC plasma concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,plasma)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  49. Area under the SNAC metabolite E494 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,plasma)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  50. Maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,plasma)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  51. Time to maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (tmax,E494,D10,plasma)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  52. Area under the SNAC metabolite E506 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,plasma)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  53. Maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,plasma)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  54. Time to maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (tmax,E506,D10,plasma)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  55. Area under the SNAC metabolite E1245 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,plasma)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  56. Maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,plasma)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  57. Time to maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (tmax,E1245,D10,plasma)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  58. Area under the SNAC metabolite E1246 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,plasma)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  59. Maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,plasma)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  60. Time to maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (tmax,E1246,D10,plasma)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  61. Area under the SNAC metabolite E1247 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,plasma)

    ng\*h/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  62. Maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,plasma)

    ng/mL

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

  63. Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)

    hours

    Time frame: From 0 to 24 hours after the 10th dosing (day 10)

07

Study locations

2 sites
  • ICON Early Phase Services, LLC
    San Antonio, Texas 78209, United States
  • ICON-Salt Lake City
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in May 2023, 20 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 20 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Mar 26, 2021
StartActual
Sep 10, 2021
Primary completionActual
May 26, 2023
CompletionActual
Jul 3, 2023
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04817644
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Sep 10, 2021
Primary completion
May 26, 2023
Completion
Jul 3, 2023
Last update
Mar 11, 2025

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion